Article
Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice.
BMC medicine - 12 Jul 2007
Hinkle Richard T, Lefever Frank R, Dolan Elizabeth T, Reichart Deborah L, Dietrich Jefferey A, Gropp Kathryn E, Thacker Robert I, Demuth Jeffrey P, Stevens Paula J, Qu Xiaoyan A, Varbanov Alex R, Wang Feng, Isfort Robert J
Abstract excerpt
BACKGROUND: Duchenne muscular dystrophy results from mutation of the dystrophin gene, causing skeletal and cardiac muscle loss of function. The mdx mouse model of Duchenne muscular dystrophy is widely utilized to evaluate the potential of therapeutic regimens to modulate the loss of skeletal muscle function associated with dystrophin mutation. Importantly, progressive loss of diaphragm function is the most...
Topics
- Animals
- Disease Models, Animal
- Disease Progression
- Dystrophin
- Gene Expression Profiling
- Gene Expression Regulation
- Male
- Mice
- Mice, Inbred mdx
- Models, Biological
- Muscles
- Muscular Dystrophy, Duchenne